Aligning Investments in Therapeutic Development with Therapeutic Need Closing the Gap (2025) / Chapter Skim
Currently Skimming:


Pages 203-218

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 203...
... APPENDIX A 203 FEBRUARY 4, 2025 The Keck Center, 500 Fifth Street, NW Washington, DC 20001 Room 105 CLOSED SESSION 8:30–1:00 Closed Session
From page 205...
... Dr. Berwick served two terms on the NAM's governing council, was a member of the NAM's Global Health Board, and currently chairs the NAM Board on Health Care Services.
From page 206...
... 206 ALIGNING INVESTMENTS IN THERAPEUTIC DEVELOPMENT the Healthcare Industry. His numerous awards include the 2007 William B
From page 207...
... She is an internationally recognized tropical and emerging disease vaccinologist, pioneering and leading innovative partnerships for vaccine development to advance a robust infectious and tropical disease vaccine portfolio.
From page 208...
... This line of research has been focused on racial and ethnic disparities in cardiovascular diseases and mental health, especially depression care.
From page 209...
... Dr. Dusetzina's work has contributed to the evidence base for the role of drug costs and coverage on patient access to care, with a specific focus on access to high-priced drugs and those for rare disease.
From page 210...
... He returned to school to get an M.B.A. and transitioned into health services administration in academic group practice and then health insurance.
From page 211...
... APPENDIX B 211 teaching, researching, and writing about related topics for many years; and currently cohosts the podcast Prescription for Better Access.
From page 212...
... Dr. Phillips brings expertise in health economics, health policy, therapeutic development, regulatory oversight, and health disparities.
From page 213...
... Salomon, Ph.D., is a professor of health policy at the Stanford University School of Medicine, senior fellow in the Freeman Spogli Institute for International Studies, and founding director of the Prevention Policy Modeling Lab. Previously, he served as policy analyst at the World Health Organization and as professor of global health at Harvard T.H.
From page 214...
... , and Apriligen, Inc. (an early-stage pediatric rare disease gene therapy company)
From page 215...
... Much of his not-for-profit as well as for-profit activities have been focused on bringing therapies to patients with high unmet needs, including those with rare diseases. He is intricately familiar with the issues that underly successful translation of research into innovation via life science companies.
From page 216...
... She was the first to quantify the contribution of innovation versus inflation in the rising trends of drug prices.
From page 217...
... Helman has led numerous activities and consensus s­ tudies, including Advancing Clinical Research with Pregnant and Lactating Popula tions, Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups, and Promising Practices to Recruit, Retain, and Advance Women in STEMM D ­ isciplines. She also led the prevention and evaluation working groups for the National Academies' Action Collaborative on Preventing Sexual Harassment in Higher Education.
From page 218...
... She obtained her B.A. in anthropology: global health and the environment with a minor in biology from Washington University in St.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.